456 Studies Now Enrolling
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 Weeks in Subjects with Non Cystic Fibrosis Bronchiectasis - The Willow Study
The Willow Study: Study of Drug in Subjects with Non Cystic Fibrosis Bronchiectasis
| Sponsor: | Insmed Incorporated |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR5818 |
| U.S. Govt. ID: | NCT03218917 |
| Contact: | Sana Sajjad: 212-304-7969 / ss4901@cumc.columbia.edu |
Additional Study Information:
The purpose of this clinical research study is to evaluate the safety and effectiveness of INS1007 as a treatment for non-CF bronchiectasis and to measure the concentration of INS1007 in the blood after treatment. INS1007 is taken as tablets and has been studied in animals and humans. Patients like you, with non CF bronchiectasis, may have problems with managing sputum movement or expectoration and worsening of respiratory symptoms. INS1007 may help manage these issues.
This study is closed
Do You Qualify?
| Have you had a history consistent with NCFBE (cough, chronic sputum production, and/or recurrent respiratory infections)? | Yes | No |
| Are you currently producing sputum and are able to provide a sputum (phlegm) sample during screening? | Yes | No |
| Have you been diagnosed with COPD, asthma, cystic fibrosis, or tuberculosis? | Yes | No |
| Are you currently a smoker? | Yes | No |
| Do you have an acute infection including respiratory infections? | Yes | No |